This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medical Info Systems Stock Outlook: Short-Term Pain to Stay
by Zacks Equity Research
The ongoing digital transition is accelerating demand for IT service solutions in healthcare despite legal and regulatory hurdles.
Why Is Omnicell (OMCL) Up 2.6% Since Its Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
Omnicell (OMCL) Down 12.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Keep Omnicell (OMCL) in Your Portfolio
by Zacks Equity Research
Omnicell (OMCL) continues to progress well with its three-legged strategy. However, escalating costs and tough hospital spending trends pose threats.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4
by Zacks Equity Research
Omnicell's (OMCL) year-over-year growth at both the segments in Q4 is encouraging.
Omnicell's Rising Costs Affect Bottom Line Amid Competition
by Zacks Equity Research
Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.
Why Is Omnicell (OMCL) Down 5% Since the Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell's Higher Investments Drive Costs, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.
Omnicell (OMCL) Gains on Product Launches, Global Expansion
by Zacks Equity Research
The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.
Omnicell (OMCL) Gains on Product Launches, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) launches AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launches XT Series Automated Supply Dispensing system.
Omnicell Upgrades Web Portal, Grows in Medication Management
by Zacks Equity Research
Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.
Omnicell (OMCL) Catches Eye: Stock Moves 13.5% Higher
by Zacks Equity Research
Omnicell, Inc. (OMCL) moved big last session, as its shares jumped over 13% on the day.
Omnicell (OMCL) Rides on Acquisitions Amid Tough Competition
by Zacks Equity Research
On Jul 4, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Why Is Omnicell (OMCL) Up 3.3% Since the Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a loss per share of 29 cents in first-quarter 2017, reflecting a deterioration from the year-ago loss of a penny.
Omnicell's Aesynt Buyout Looks Promising amid Several Woes
by Zacks Equity Research
On Apr 6, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Why Is Omnicell (OMCL) Up 3% Since the Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise
by Zacks Equity Research
On Feb 22, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.
Omnicell Partners with DCH Health for Sterile Compounding
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.
Omnicell Unveils XT Series Automated Dispensing System
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently introduced a new generation of medication and supply automation that is fully integrated with the company's Unity enterprise platform -- XT series.
Omnicell to Buy Ateb, Expand in Adherence Tools Market
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently inked a deal to buy pharmacy-based patient care solution provider Ateb, Inc and its Canadian affiliate, Ateb Canada Ltd.